Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of combining two drugs, cabozantinib and nivolumab, in treating patients with advanced melanoma or squamous cell head and neck cancer that may have spread to nearby tissues, lymph nodes, or distant parts of the body. This phase II study aims to assess how quickly patients can be grouped based on tumor biomarkers called tumor mutational burden and tumor inflammation signature, and to learn if the combination can shrink or stabilize the cancer depending on these biomarker statuses. Participants receive nivolumab through an intravenous infusion on the first day of each 28-day treatment cycle and take cabozantinib orally daily. Treatment cycles continue for up to two years unless the cancer progresses or unacceptable side effects occur. Throughout the trial, patients undergo CT or MRI scans and blood sample collections. Tumor biopsies are taken during screening and optionally during follow-up. After completing treatment, participants are followed up every 12 weeks for one year and then every six months up to three years after registration. During the study, patients will be monitored with imaging scans and laboratory tests to assess tumor response and safety. Researchers will measure how quickly biomarker results are available and evaluate overall response rates, disease control, progression-free survival, and overall survival over two years. Safety and tolerability of the drug combination will also be assessed, along with the identification of biomarkers that might predict treatment response or side effects. Specimens will be collected and stored for future research.
Actively Recruiting
Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.
Actively Recruiting
Researchers are evaluating radiation therapy with or without the chemotherapy drug cisplatin in patients with stage III-IVA squamous cell carcinoma of the head and neck who have had surgery to remove their tumor. This phase II trial aims to understand if adding cisplatin to radiation therapy improves disease-free survival, especially in relation to different types of p53 gene mutations, which might affect treatment outcomes. The study also looks at side effects and explores genetic changes that could influence new treatments. Participants are randomly assigned to one of two groups one group receives intensity-modulated radiation therapy IMRT alone once daily, five days a week for six weeks, while the other group receives the same radiation schedule combined with weekly intravenous cisplatin over 1 to 2 hours for six weeks. After completing treatment without disease progression or unacceptable side effects, patients enter a follow-up period lasting up to 10 years. During the study, participants undergo assessments including surgical tumor tissue analysis for p53 mutations, imaging tests to exclude distant disease, and regular health evaluations. After treatment, patients are monitored every six months for three years and then annually for seven more years to track disease recurrence or new tumors. The main outcome measured is disease-free survival, focusing on the time from randomization to recurrence, second primary tumor, or death.
Actively Recruiting
Researchers are evaluating targeted cancer treatments directed by genetic testing for patients with locally advanced or advanced solid tumors. This ComboMATCH patient screening trial is designed to match patients with specific genetic mutations in their tumor cells to investigational combination therapies. Patients included have tumors that have spread or progressed after standard treatments, or have no standard treatment proven to extend survival. The study aims to improve treatment planning by using genetic information to assign therapies. Participants undergo tumor mutational screening using previously collected tumor samples. Eligible patients aged 18 and older with biopsiable disease may have a new biopsy before starting treatment. Those with relevant mutations are assigned to one of 20 treatment subprotocols involving various drug combinations and regimens, including oral, intravenous, and intramuscular administration. Treatments are given in repeated 28-day cycles, continuing without disease progression or unacceptable toxicity. The trial includes multiple arms and cohorts tailored to specific genetic alterations and cancer types, with some allowing crossover if disease progresses. Throughout the study, participants have tumor biopsies, blood collections, imaging tests such as CT, MRI, PET scans, and cardiac assessments like echocardiograms or MUGA scans. Bone marrow aspirations or biopsies, bone scans, and brain imaging may also be performed as clinically indicated. Researchers measure patient enrollment and treatment assignment, as well as positive treatment outcomes in defined molecular cohorts. The trial may last up to 8 years, with ongoing monitoring and optional additional biopsies at disease progression to assess treatment effects and safety.
Actively Recruiting
Researchers are comparing early versus delayed treatment using venetoclax and obinutuzumab in patients newly diagnosed with high-risk chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This phase III trial aims to see if starting treatment before symptoms appear improves overall survival and other outcomes. Venetoclax is a BCL-2 inhibitor that may stop cancer cell growth, and obinutuzumab is a monoclonal antibody that may help the immune system attack cancer cells. Participants are randomly assigned to one of two groups one begins treatment early after meeting eligibility criteria, and the other starts treatment only after symptoms develop. Both groups receive obinutuzumab intravenously on specified days during the first six cycles and venetoclax orally daily during later cycles, with treatment repeated every 28 days for up to 12 cycles. During and after treatment, patients undergo CT scans, blood sample collections, and bone marrow biopsies. Participants are monitored for up to 10 years after treatment to assess overall survival, progression-free survival, response rates, safety, and quality of life using the FACT-Leukemia scale. Researchers collect various samples and data, including measurable residual disease status and biomarkers. Patient compliance and adverse events are also tracked to better understand the treatment effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating a combination therapy for adults with newly diagnosed multiple myeloma not intended for early autologous transplantation. This phase III trial compares a four-drug regimen including daratumumab, bortezomib, lenalidomide, and dexamethasone to a three-drug regimen of daratumumab, lenalidomide, and dexamethasone. The study aims to determine if adding bortezomib improves overall survival and progression-free survival in patients with different minimal residual disease statuses, while also assessing side effects and patient-reported outcomes. All participants first receive standard induction therapy with daratumumab given subcutaneously on specific days, lenalidomide orally daily for 21 days, and dexamethasone orally on certain days, repeated every 28 days for 9 cycles. After induction, patients are randomly assigned to one of two consolidation and maintenance arms one adding bortezomib to the consolidation phase followed by maintenance with daratumumab and lenalidomide, and the other continuing with daratumumab, lenalidomide, and dexamethasone for consolidation and maintenance. Treatments continue in cycles of 28 days unless disease progresses or unacceptable side effects occur. During the study, participants undergo various assessments including bone marrow aspirates, blood tests, imaging with PETCT scans, and patient-reported quality of life evaluations. Researchers monitor overall survival, progression-free survival, response rates, adverse events, and neuropathy symptoms over periods up to 15 years. Follow-up visits occur every 3 months for up to 2 years, then less frequently, ensuring long-term monitoring of treatment effects and safety.